Abstract:The peptidoglycan-polysaccharide (PGPS) model shares many etiologic and pathologic features with Crohn's disease (CD).Anti-TNFα therapy reduces both inflammation and fibrosis in the PGPS model if begun early but, as in CD, has diminished efficacy when instituted late in the course of the model.To begin to tease out the mechanism of diminished anti-TNFα efficacy in advanced disease, we examined changes in mRNA levels of a broad panel of proinflammatory and profibrotic factors over time in the PGPS model.Methods: PGPS or human serum albumin (HSA, control) was injected into the bowel wall of Lewis rats at laparotomy.Rats (1 HSA, 3 PGPS) were euthanized at each time point (1, 4, 7, 11, 14, 21, and 28 d post injection).Non-operated rats (3) served as d0 controls.In separate experiments, rats received Ab501 (CA156_00501 Fab'-PEG; a pegylated murinized rabbit anti-mouse TNF) beginning on d1 or d13.Rats receiving anti-TNF were studied on d12 or d28.Gross abdominal score (sum of adhesions, mesenteric thickening, cecal wall thickening, cecal nodules, and liver nodules on 0-4 scales) was determined.A pathologist scored cecal sections.Quantitative real-time PCR was performed on cecal tissue.Results: IL1 β, IL6, TNFα, and TGFβ1 mRNAs showed a biphasic response, peaking at d1 and again at d11 post PGPS injection (previously shown).The second peak at d11 was accompanied by maximal mRNA levels of Th1 (IFNγ, IL2) and Th17 (IL17A) cytokines, IL23, granulocyte-macrophage colony stimulating factor (GM-CSF), monocyte chemotactic protein-1, arginase-1, tissue transglutaminase 2, and tissue inhibitor of metalloproteinase 1. Osteopontin mRNA was maximally elevated at d1 (.500-fold), then progressively declined to ~40-fold control at d21-28.IL13 mRNA was not elevated.Anti-TNF begun on d1 decreased expression of IL1 β (5.5±1.8 v 12.8±1.2,p=0.014) and IL6 (11.2±6.6 v 51.5±7.6,p=0.008) when assessed on day 12. Anti-TNF begun on d13 did not change expression of TNF α, IL1β, IL6 mRNAs; procollagens I and III trended higher on d21 (col I: 23.1±6.2v 11.6±1.9,p=0.07; col III: 14.7±2.1 v 9.14±1.7,p=0.06).Conclusions: The robust Th17 response and increased GM-CSF near the midpoint of the PGPS model time course may render the ongoing immune response no longer controllable by targeting TNF α alone.Blockade of TNF α activity initiated at times in the course of disease when TGF β1 mRNA expression is maximal could exaggerate the results of loss of TNF α inhibitory effects on TGF β profibrotic activity.This could explain why anti-TNFα begun on d13 results in increased collagen mRNA at d21.Decreased tissue compliance, suggested by increased collagen deposition at d7, may play a role in triggering the d7-11 wave of increased profibrotic and proinflammatory factors.Cytokine milleu and tissue factors likely determine the effect of anti-TNF on tissue inflammation and fibrosis.

Sa1871 Intestinal Epithelial Vitamin D Receptor Signaling Suppresses Colitis by Protecting the Mucosal Epithelial Barrier

PDE9 Inhibitor PF-04447943 Attenuates DSS-Induced Colitis by Suppressing Oxidative Stress, Inflammation, and Regulating T-Cell Polarization

Sa1797 Cell Cycle Arrest, DNA Damage and Remodeling of the Colonic Epithelial Barrier Composition and Function Underlies DSS-Induced Colitis

Epithelial CRL4 DCAF2 is Critical for Maintaining Intestinal Homeostasis Against DSS-Induced Colitis by Regulating the Proliferation and Repair of Intestinal Epithelial Cells

Gut Epithelial Vitamin D Receptor Regulates Microbiota-Dependent Mucosal Inflammation by Suppressing Intestinal Epithelial Cell Apoptosis

Intestinal epithelial vitamin D receptor signaling inhibits experimental colitis.

Paneth Cell Alertness to Pathogens Maintained by Vitamin D Receptors

Proteolytic bacteria expansion during colitis amplifies inflammation through cleavage of the external domain of PAR2

Expression of proteinase activated receptor-2 in intestinal mucosa of patients with ulcerative colitis

Intestinal epithelial specific AhR deficient mice exhibit increased severity of experimentally induced chronic colitis

Overexpression of Vitamin D Receptor in Intestinal Epithelia Protects Against Colitis via Upregulating Tight Junction Protein Claudin 15.

Ursolic Acid Regulates Intestinal Microbiota and Inflammatory Cell Infiltration to Prevent Ulcerative Colitis

Epithelial PBLD attenuates intestinal inflammatory response and improves intestinal barrier function by inhibiting NF-κB signaling

Targeting Desulfovibrio vulgaris flagellin-induced NAIP/NLRC4 inflammasome activation in macrophages attenuates ulcerative colitis

P124 Tissue Factor and Protease-Activated Receptor 2 associated genes are upregulated in patients with Inflammatory Bowel Disease

Lactobacillus paracasei Jlus66 relieves DSS-induced ulcerative colitis in a murine model by maintaining intestinal barrier integrity, inhibiting inflammation, and improving intestinal microbiota structure

Role and significance of lymphotoxin α1/β2 and its receptor LTβR in intestinal mucosal immunity of ulcerative colitis

Epithelial aryl hydrocarbon receptor regulates IL-22 producing colonic group 3 innate lymphoid cells to augment microbial metabolite mediated protection in colitis

miRNA-133a-UCP2 pathway regulates inflammatory bowel disease progress by influencing inflammation, oxidative stress and energy metabolism.

Ion Transport Basis of Diarrhea, Paneth Cell Metaplasia, and Upregulation of Mechanosensory Pathway in Anti-CD40 Colitis Mice

Intestinal Inflammation and Regeneration–Interdigitating Processes Controlled by Dietary Lipids in Inflammatory Bowel Disease